Lion Biotechnologies Inc. (LBIO) 7.4500 $LBIO
Lion Biotechnologies Obtains Exclusive License From NIH for Next-Generation TIL Technology
GlobeNewswire - Wed Feb 11, 9:55AM CST
Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that it has obtained an exclusive, worldwide license from the National Institutes of Health (NIH) to intellectual property related for a next-generation TIL technology for the treatment of metastatic melanoma. This announcement follows a separate exclusive licensing agreement with the NIH for other TIL technologies, which was announced earlier this week.
Lion Biotechnologies Obtains Exclusive License From NIH to Develop and Commercialize TIL Therapy in Metastatic Melanoma
GlobeNewswire - Tue Feb 10, 8:07AM CST
Lion Biotechnologies, Inc. (LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that it has obtained an exclusive, worldwide license from the National Institute of Health (NIH) to certain patents to develop and commercialize TIL therapy in the treatment of metastatic melanoma.
Lion Biotechnologies Announces Allowance of IND Application to Begin New Phase 2 Study in Metastatic Melanoma
GlobeNewswire - Mon Feb 02, 9:05AM CST
Lion Biotechnologies, Inc. (LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that the US Food and Drug Administration (FDA) has allowed its investigational new drug (IND) application to initiate a Phase 2 study of its lead product candidate, LN-144, in the treatment of refractory metastatic melanoma.
Lion Biotechnologies Amends CRADA With National Cancer Institute to Develop TIL Therapy for Additional Cancer Indications
GlobeNewswire - Mon Jan 26, 7:10AM CST
Lion Biotechnologies, Inc. (LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that its existing Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) has been amended to include four new tumor indications for TIL therapy.
Lion Biotechnologies CSO Laszlo Radvanyi Co-authors Study in Clinical Cancer Research
GlobeNewswire - Mon Jan 12, 8:16AM CST
Lion Biotechnologies, Inc. (LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL), today announced that research by chief scientific officer Laszlo Radvanyi, PhD, has been published in Clinical Cancer Research. The research, which Dr. Radvanyi conducted at MD Anderson Cancer Center with his former colleagues, validates a groundbreaking method of accelerating the production of TIL, while enhancing their ability to survive and target tumor-specific antigens.
Lion Biotechnologies to Present at Biotech Showcase
GlobeNewswire - Tue Jan 06, 7:07AM CST
Lion Biotechnologies, Inc. (LBIO) announced that president and CEO Elma Hawkins, PhD, will present at the Biotech Showcase on Monday, January 12, 2015. The conference is being held at the Parc 55 Wyndham Union Square Hotel in San Francisco. Dr. Hawkins will present at 3 p.m. PST in the Powell room on the third floor.
Lion Biotechnologies Submits Investigational New Drug Application to Conduct Phase 2 Study in Metastatic Melanoma
GlobeNewswire - Mon Jan 05, 7:25AM CST
Lion Biotechnologies, Inc., a biotechnology company that is developing novel cancer immunotherapies, today announced that it has filed an investigational new drug (IND) application with the United States Food and Drug Administration to conduct a Phase 2 clinical trial of the company's lead product candidate, LN-144, in the treatment of patients with refractory metastatic melanoma. LN-144 is a cell product of autologous tumor infiltrating lymphocytes (TIL) derived from the patient's tumor.
Lion Biotechnologies Announces Closing of Underwritten Common Stock Offering
GlobeNewswire - Mon Dec 22, 3:10PM CST
Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL), today announced the closing of its underwritten offering of 6,000,000 shares of its common stock at $5.75 per share, including 782,608 shares sold pursuant to the exercise in full of the underwriters' option to purchase additional shares, resulting in gross proceeds from the offering of $34.5 million before deducting underwriting discounts and commissions and offering expenses payable by Lion.
Lion Bio prices offering
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 8:49AM CST
Lion Biotechnologies Announces Pricing of Underwritten Common Stock Offering
GlobeNewswire - Wed Dec 17, 8:36AM CST
Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL), today announced the pricing of an underwritten offering of 5,217,392 shares of its common stock at a price of $5.75 per share, for gross proceeds of $30.0 million. All of the shares in the offering are being sold by Lion. The net proceeds from the offering are expected to be approximately $28.0 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by Lion.
Lion Biotechnologies Names Elma Hawkins President, Chief Executive Officer and Director
GlobeNewswire - Mon Dec 15, 7:02AM CST
Lion Biotechnologies, Inc., a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL), today announced that its board of directors has appointed Elma Hawkins, PhD, to serve as its president and chief executive officer, effective January 1, 2015, and appointed Dr. Hawkins as a director, effective immediately.
Lion Biotechnologies Announces Positive New Data From Lead TIL Melanoma Program at ASH
GlobeNewswire - Mon Dec 08, 7:00AM CST
Lion Biotechnologies, Inc. (LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TILs) under a Cooperative Research and Development Agreement with the National Cancer Institute (NCI), today announced that Steven A. Rosenberg, MD, PhD, chief of surgery at the NCI, presented positive, new data from a Phase 2 clinical trial of TIL therapy in metastatic melanoma. The updated results were presented on December 7, 2014 in a scientific symposium on adoptive T-cell therapy (ACT) at the American Society of Hematology annual meeting in San Francisco, CA.
Lion Biotechnologies to Present at the Piper Jaffray 26th Annual Healthcare Conference
GlobeNewswire - Mon Dec 01, 7:00AM CST
Lion Biotechnologies, Inc. (LBIO), a biotechnology company focused on the development and commercialization of novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TILs), today announced that President and Chief Operating Officer, Elma Hawkins, Ph.D., will present at the Piper Jaffray 26th Annual Healthcare Conference on Wednesday, December 3, 2014, at 4:00 p.m. Eastern. The conference is being held at The New York Palace Hotel, from December 2-3, 2014.
Lion Biotechnologies Announces Clinical Data Update at American Society of Hematology Annual Meeting
GlobeNewswire - Fri Nov 21, 7:07AM CST
Lion Biotechnologies, Inc. (LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TILs) under a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) , today announced that Steven A. Rosenberg, M.D. Ph.D., chief of surgery at the NCI and principal investigator of the CRADA, will provide an update on a Phase 2 clinical trial in patients with metastatic melanoma at the American Society of Hematology (ASH) annual meeting in San Francisco. The data will be presented in a special scientific symposium on adoptive T-cell therapy (ACT) to treat cancers on December 7 from 9:30 to 11:00 a.m. PST.
More Fallout From Stock Promotion Scandal
Richard Pearson - Seeking Alpha - Fri Nov 14, 1:35PM CST
Back in March, I highlighted the undisclosed paid stock promotions being run by the Dream Team Group in connection with CytRX (NASDAQ: CYTR ) and Galena (NASDAQ: GALE ). In the wake of that scandal, we have seen both of their stock prices plunge by...
CYTR: 2.96 (+0.23), GALE: 1.68 (+0.06)
Lion Bio chief resigns
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 4:06PM CST
Lion Biotechnologies Announces Management Change
GlobeNewswire - Wed Nov 12, 3:06PM CST
Lion Biotechnologies, Inc. (OTCBB:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes (TILs), today announced that its chief executive officer Manish Singh, PhD, is resigning for personal reasons, effective December 31, 2014. In addition, Dr. Singh is stepping down as a director of Lion, effective immediately. The company's board of directors intends to appoint a new CEO prior to Dr. Singh's departure.
The most undervalued, yet comprehensive cancer immunotherapy in development?
ACCESSWIRE - Mon Nov 03, 7:03AM CST
Los Angeles, CA / ACCESSWIRE / November 3, 2014 / The National Cancer Institute (NCI) spends upwards of $4.9 billion each year on cancer research.
INO: 6.80 (-0.15), NWBO: 6.07 (+0.13), DNDN: 0.13 (-0.02), GALE: 1.68 (+0.06)
Lion Biotechnologies CSO Laszlo Radvanyi Co-Authors Study in Journal of Immunotherapy
GlobeNewswire - Mon Oct 20, 8:37AM CDT
Lion Biotechnologies, Inc. (OTCBB:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes (TILs), today announced that research by chief scientific officer Laszlo Radvanyi, PhD, has been published in the current issue of Journal of Immunotherapy. The research, which Dr. Radvanyi conducted with former colleagues at MD Anderson Cancer Center, validates a more practical and cost-efficient method of manufacturing TIL therapy for the treatment of metastatic melanoma.
Lion Biotechnologies to Present at the Rodman & Renshaw 16th Annual Global Investment Conference
GlobeNewswire - Fri Sep 05, 8:46AM CDT
Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company focused on the development and commercialization of novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TILs), today announced that Chief Executive Officer Manish Singh, Ph.D., will present at the Rodman & Renshaw 16th Annual Global Investment Conference on Tuesday, September 9, 2014, at 9:35 a.m. Eastern in Holmes II Salon (4th floor). The conference is being held at The New York Palace Hotel from September 8-10, 2014.
Lion Biotechnologies Obtains Exclusive License From NIH for Next-Generation TIL Technology
GlobeNewswire - Wed Feb 11, 9:55AM CST
Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that it has obtained an exclusive, worldwide license from the National Institutes of Health (NIH) to intellectual property related for a next-generation TIL technology for the treatment of metastatic melanoma. This announcement follows a separate exclusive licensing agreement with the NIH for other TIL technologies, which was announced earlier this week.
Lion Biotechnologies Obtains Exclusive License From NIH to Develop and Commercialize TIL Therapy in Metastatic Melanoma
GlobeNewswire - Tue Feb 10, 8:07AM CST
Lion Biotechnologies, Inc. (LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that it has obtained an exclusive, worldwide license from the National Institute of Health (NIH) to certain patents to develop and commercialize TIL therapy in the treatment of metastatic melanoma.
Lion Biotechnologies Announces Allowance of IND Application to Begin New Phase 2 Study in Metastatic Melanoma
GlobeNewswire - Mon Feb 02, 9:05AM CST
Lion Biotechnologies, Inc. (LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that the US Food and Drug Administration (FDA) has allowed its investigational new drug (IND) application to initiate a Phase 2 study of its lead product candidate, LN-144, in the treatment of refractory metastatic melanoma.
Lion Biotechnologies Amends CRADA With National Cancer Institute to Develop TIL Therapy for Additional Cancer Indications
GlobeNewswire - Mon Jan 26, 7:10AM CST
Lion Biotechnologies, Inc. (LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that its existing Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) has been amended to include four new tumor indications for TIL therapy.
Lion Biotechnologies CSO Laszlo Radvanyi Co-authors Study in Clinical Cancer Research
GlobeNewswire - Mon Jan 12, 8:16AM CST
Lion Biotechnologies, Inc. (LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL), today announced that research by chief scientific officer Laszlo Radvanyi, PhD, has been published in Clinical Cancer Research. The research, which Dr. Radvanyi conducted at MD Anderson Cancer Center with his former colleagues, validates a groundbreaking method of accelerating the production of TIL, while enhancing their ability to survive and target tumor-specific antigens.
Lion Biotechnologies to Present at Biotech Showcase
GlobeNewswire - Tue Jan 06, 7:07AM CST
Lion Biotechnologies, Inc. (LBIO) announced that president and CEO Elma Hawkins, PhD, will present at the Biotech Showcase on Monday, January 12, 2015. The conference is being held at the Parc 55 Wyndham Union Square Hotel in San Francisco. Dr. Hawkins will present at 3 p.m. PST in the Powell room on the third floor.
Lion Biotechnologies Submits Investigational New Drug Application to Conduct Phase 2 Study in Metastatic Melanoma
GlobeNewswire - Mon Jan 05, 7:25AM CST
Lion Biotechnologies, Inc., a biotechnology company that is developing novel cancer immunotherapies, today announced that it has filed an investigational new drug (IND) application with the United States Food and Drug Administration to conduct a Phase 2 clinical trial of the company's lead product candidate, LN-144, in the treatment of patients with refractory metastatic melanoma. LN-144 is a cell product of autologous tumor infiltrating lymphocytes (TIL) derived from the patient's tumor.
Lion Biotechnologies Announces Closing of Underwritten Common Stock Offering
GlobeNewswire - Mon Dec 22, 3:10PM CST
Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL), today announced the closing of its underwritten offering of 6,000,000 shares of its common stock at $5.75 per share, including 782,608 shares sold pursuant to the exercise in full of the underwriters' option to purchase additional shares, resulting in gross proceeds from the offering of $34.5 million before deducting underwriting discounts and commissions and offering expenses payable by Lion.
Lion Bio prices offering
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 8:49AM CST
Lion Biotechnologies Announces Pricing of Underwritten Common Stock Offering
GlobeNewswire - Wed Dec 17, 8:36AM CST
Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL), today announced the pricing of an underwritten offering of 5,217,392 shares of its common stock at a price of $5.75 per share, for gross proceeds of $30.0 million. All of the shares in the offering are being sold by Lion. The net proceeds from the offering are expected to be approximately $28.0 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by Lion.
Lion Biotechnologies Names Elma Hawkins President, Chief Executive Officer and Director
GlobeNewswire - Mon Dec 15, 7:02AM CST
Lion Biotechnologies, Inc., a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL), today announced that its board of directors has appointed Elma Hawkins, PhD, to serve as its president and chief executive officer, effective January 1, 2015, and appointed Dr. Hawkins as a director, effective immediately.
Lion Biotechnologies Announces Positive New Data From Lead TIL Melanoma Program at ASH
GlobeNewswire - Mon Dec 08, 7:00AM CST
Lion Biotechnologies, Inc. (LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TILs) under a Cooperative Research and Development Agreement with the National Cancer Institute (NCI), today announced that Steven A. Rosenberg, MD, PhD, chief of surgery at the NCI, presented positive, new data from a Phase 2 clinical trial of TIL therapy in metastatic melanoma. The updated results were presented on December 7, 2014 in a scientific symposium on adoptive T-cell therapy (ACT) at the American Society of Hematology annual meeting in San Francisco, CA.
Lion Biotechnologies to Present at the Piper Jaffray 26th Annual Healthcare Conference
GlobeNewswire - Mon Dec 01, 7:00AM CST
Lion Biotechnologies, Inc. (LBIO), a biotechnology company focused on the development and commercialization of novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TILs), today announced that President and Chief Operating Officer, Elma Hawkins, Ph.D., will present at the Piper Jaffray 26th Annual Healthcare Conference on Wednesday, December 3, 2014, at 4:00 p.m. Eastern. The conference is being held at The New York Palace Hotel, from December 2-3, 2014.
Lion Biotechnologies Announces Clinical Data Update at American Society of Hematology Annual Meeting
GlobeNewswire - Fri Nov 21, 7:07AM CST
Lion Biotechnologies, Inc. (LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TILs) under a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) , today announced that Steven A. Rosenberg, M.D. Ph.D., chief of surgery at the NCI and principal investigator of the CRADA, will provide an update on a Phase 2 clinical trial in patients with metastatic melanoma at the American Society of Hematology (ASH) annual meeting in San Francisco. The data will be presented in a special scientific symposium on adoptive T-cell therapy (ACT) to treat cancers on December 7 from 9:30 to 11:00 a.m. PST.
More Fallout From Stock Promotion Scandal
Richard Pearson - Seeking Alpha - Fri Nov 14, 1:35PM CST
Back in March, I highlighted the undisclosed paid stock promotions being run by the Dream Team Group in connection with CytRX (NASDAQ: CYTR ) and Galena (NASDAQ: GALE ). In the wake of that scandal, we have seen both of their stock prices plunge by...
CYTR: 2.96 (+0.23), GALE: 1.68 (+0.06)
Lion Bio chief resigns
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 4:06PM CST
Lion Biotechnologies Announces Management Change
GlobeNewswire - Wed Nov 12, 3:06PM CST
Lion Biotechnologies, Inc. (OTCBB:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes (TILs), today announced that its chief executive officer Manish Singh, PhD, is resigning for personal reasons, effective December 31, 2014. In addition, Dr. Singh is stepping down as a director of Lion, effective immediately. The company's board of directors intends to appoint a new CEO prior to Dr. Singh's departure.
The most undervalued, yet comprehensive cancer immunotherapy in development?
ACCESSWIRE - Mon Nov 03, 7:03AM CST
Los Angeles, CA / ACCESSWIRE / November 3, 2014 / The National Cancer Institute (NCI) spends upwards of $4.9 billion each year on cancer research.
INO: 6.80 (-0.15), NWBO: 6.07 (+0.13), DNDN: 0.13 (-0.02), GALE: 1.68 (+0.06)
Lion Biotechnologies CSO Laszlo Radvanyi Co-Authors Study in Journal of Immunotherapy
GlobeNewswire - Mon Oct 20, 8:37AM CDT
Lion Biotechnologies, Inc. (OTCBB:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes (TILs), today announced that research by chief scientific officer Laszlo Radvanyi, PhD, has been published in the current issue of Journal of Immunotherapy. The research, which Dr. Radvanyi conducted with former colleagues at MD Anderson Cancer Center, validates a more practical and cost-efficient method of manufacturing TIL therapy for the treatment of metastatic melanoma.
Lion Biotechnologies to Present at the Rodman & Renshaw 16th Annual Global Investment Conference
GlobeNewswire - Fri Sep 05, 8:46AM CDT
Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company focused on the development and commercialization of novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TILs), today announced that Chief Executive Officer Manish Singh, Ph.D., will present at the Rodman & Renshaw 16th Annual Global Investment Conference on Tuesday, September 9, 2014, at 9:35 a.m. Eastern in Holmes II Salon (4th floor). The conference is being held at The New York Palace Hotel from September 8-10, 2014.
